Huma.AI

Huma.AI is a company that provides a generative AI platform for the life sciences industry. The company's self-service business intelligence platform is designed to simplify real-world data (RWD) analysis and automate post-market insight for its customers. Huma.AI's technology assists clients in gaining vital knowledge about their products from multiple departments within their organizations, enabling them to make crucial product changes based on this data.

The platform leverages machine learning (ML) and natural language processing (NLP) technologies to speed up the process of reviewing and analyzing literature and post-market performance data. It automatically curates articles and other data most relevant to post-market surveillance, allowing for quicker evaluation of product effectiveness for regulatory compliance and guiding product strategy. Huma.AI's platform is particularly advantageous for exploring unstructured data, which accounts for approximately 80% of healthcare data. The company claims that its platform enables users to extract key insights across millions of documents or billions of rows of unorganized texts more accurately in minutes rather than months.

In February 2022, Huma.AI expanded its platform to include a post-market surveillance (PMS) solution specifically designed to help device and in vitro diagnostic (IVD) manufacturers meet new compliance and oversight requirements mandated by the European Union's Medical Device Regulation (EU MDR) and In Vitro Diagnostic Medical Device Regulation (IVDR). This solution aims to actively and systematically gather, record, and analyze relevant data on the quality, performance, and safety of a device throughout its entire lifetime. According to the company, this PMS solution has been validated by customers to shorten the time spent on literature searches from weeks to minutes with a 10x increase in accuracy.

Huma.AI's annual revenues reportedly tripled during 2021. The company's platform supports various use cases, including medical affairs, clinical development, real-world evidence, and post-market surveillance. Its technology allows for rapid development of new use cases and expansion into adjacent sub-verticals.